Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | See Remarks | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 147,845 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 23,116 · Balance 147,845 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 79,936 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 79,936 · Balance 79,936 F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 5, 2018 21:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016446 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,624 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 185 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:16 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 282 | $56.61 | $15,964.02 |
DisclosureSEC source: 0001209191-17-036975 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,939 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| May 05, 2017 Filed May 8, 2017 21:38 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 705 | $61.08 | $43,061.40 |
DisclosureSEC source: 0001209191-17-030641 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,221 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. F2 · balance_after: Includes 131 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (RIght to Buy) · Derivative | 15,000 | $0.00 Strike: $88.80 | $0.00 |
DisclosureSEC source: 0001209191-17-016059 · doc4.xml · derivative · entry 2 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:39 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016059 · doc4.xml · nonDerivative · entry 1 Huang Dennis Karl · CIK 0001641217 · EVP & Chief Tech Ops Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,795 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.